Skip to main content
SpringerLink
Log in

Adjuvant Chemotherapy of Cancer

A Review of its Current Status

  • Review Article
  • Published:
Drugs Aims and scope Submit manuscript

Summary

Adjuvant chemotherapy can be defined as the use of drugs immediately after local control therapy to attempt eradication of residual micrometastatic disease. Conceptually, the micrometastatic disease is presumed to be outside the field of surgical excision or the area of curative intent of radiation therapy. Adjuvant chemotherapy designed to eradicate established micrometastases is a relatively new area of clinical research which began to be seriously considered in the late 1960s and reached a peak of enthusiasm a decade later. However, the early promise of adjuvant chemotherapy has not been fulfilled and the entire concept, and its biological underpinnings, are now under re-evaluation.

This review considers the biological rationale for adjuvant chemotherapy and the current status of the large-scale clinical trial data base which now exists in 4 major diseases: breast cancer, osteogenic sarcoma, large bowel cancer, and gastric cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Ahmann DL, Payne WS, Scanion PW, O’Fallon JR, Bisel HF, et al. Repeated adjuvant chemotherapy with phenylalanine mustard or 5-fluorouracil: Cyclphosphamide, and prednisone with or without radiation, after mastectomy for breast cancer. Lancet 1: 983, 1978

    Google Scholar 

  • Alexander P. 2nd Gordon Hamilton Fairley Lecture. Need for new approaches to the treatment of patients in clinical remission with special reference to acute myeloid leukemia. British Journal of Cancer 46: 151–159, 1982

    CAS  Google Scholar 

  • Bonadonna G, Brusamolino E, Valagussa P, et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. New England Journal of Medicine 294: 405, 1976

    Article  PubMed  CAS  Google Scholar 

  • Bonadonna G, Rossi A, Valagussa P, et al. Adjuvant chemotherapy with CMF in breast cancer with positive axillary nodes. In Salmon and Jones (Eds) Adjuvant Therapy of Cancer, pp. 83–95 (North-Holland Publishing Co, Amsterdam, Oxford, New York, 1977

    Google Scholar 

  • Bonadonna G, Valagussa P. Dose-response effect of CMF chemotherapy in breast cancer. New England Journal of Medicine 304: 10–15, 1981

    Article  PubMed  CAS  Google Scholar 

  • Bonadonna G, Valagussa P. Chemotherapy of breast cancer: current views of results. International Journal of Radiation Oncology Biophysics 9: 279–297, 1983

    Article  CAS  Google Scholar 

  • Bonadonna G, Valagussa P, Rossi A, Tancini G, Bajetta E, et al. CMF Adjuvant chemotherapy in operable breast cancer. In Salmon & Jones (Eds) Adjuvant Therapy of Cancer, II, Grune and Stratton, New York, 1979

    Google Scholar 

  • Bonadonna G, Valagussa P, Rossi A, et al. Multimodal therapy with CMF in resectable breast cancer with positive axillary nodes: The Milan experience. In Salmon and Jones (Eds) Adjuvant Therapy of Cancer, III, pp. 435–445 (Grune and Stratton, New York 1981

    Google Scholar 

  • Caprini JA, Oviedu MA, Cunningham MP, et al. Adjuvant chemotherapy for stage II and IN breast carcinoma. Journal of the American Medical Association 244: 243–246, 1980

    Article  PubMed  CAS  Google Scholar 

  • Carter SK. Adjuvant chemotherapy of osteogenic sarcoma. In Carter et al. (Eds) Principles of Cancer Treatment, pp. 712–718 McGraw-Hill, New York, 1982

    Google Scholar 

  • Cooper MR, Rhyne AL, Muss HB, et al. A randomized comparative trial of chemotherapy and irradiation therapy for stage II breast cancer. Cancer 47: 2833–2839, 1981

    Article  PubMed  CAS  Google Scholar 

  • Coronary Drug Project Research Group: Influence of adherence to treatment and response of cholesterol on mortality in the Coronary Drug Project. New England Journal of Medicine 303: 1038–1041, 1980

    Article  Google Scholar 

  • Cortes EP, Holland JF, Wang JJ, et al. Amputation and Adriamycin in primary osteogenic sarcoma. New England Journal of Medicine 291: 998, 1974

    Article  PubMed  CAS  Google Scholar 

  • Cortes EP, Necheles TF, Holland JF, et al. Adjuvant chemotherapy for primary osteosarcoma: A cancer and leukemia group B experience. In Salmon & Jones (Eds) Adjuvant Therapy of Cancer, III, pp. 201–210 Grune and Stratton, New York, 1981

    Google Scholar 

  • De Cosse JJ. Are we doing better with large bowel cancer? New England Journal of Medicine 310: 782–783, 1984

    Article  Google Scholar 

  • Depeyster FA, Gilchrist RK. Pathology and manifestations of cancer of the colon and rectum. In Turrel (Ed.) Diseases of the Colon and Anorectum, pp. 428–452 Saunders, Philadelphia 1969

    Google Scholar 

  • DeVita Jr VT. The James Lewing Lecture. The relationship between tumor mass and resistance to chemotherapy: Implications for surgical adjuvant treatment of cancer. Cancer 51: 1209–1220, 1983

    Google Scholar 

  • De Wys WD. Studies correlating the growth rate of a tumor and its metastases and providing evidence for tumor-related systemic growth-retarding factors. Cancer Research 32: 374–379, 1972

    Google Scholar 

  • Douglas HO. Potentially curable cancer of the stomach. Cancer 50: 2582–2589, 1979

    Google Scholar 

  • Dixon WJ, Longmire WP, Holden WD. Use of triethylene-thiophosphoramide as an adjuvant to the surgical treatment of gastric and colorectal carcinoma: Ten-year follow-up. Annals of Surgery 173: 26–39, 1971

    Article  PubMed  CAS  Google Scholar 

  • Edmonson JH, Green SJ, Ivins JC, et al. Methotrexate as adjuvant treatment for primary osteosarcoma. New England Journal of Medicine 303: 642, 1980

    PubMed  CAS  Google Scholar 

  • Eilber FR, Eckhardt J. Adjuvant therapy for osteosarcoma: a randomized prospective trial. Proceedings of the ASCO 4: 144, 1985

    Google Scholar 

  • Fidler IJ. Tumor heterogeneity and the biology of cancer invasion and metastases. Cancer Research 38: 2651–2660, 1978

    PubMed  CAS  Google Scholar 

  • Fidler IJ, Kripke ML. Metastasis results from pre-existing variant cells within a malignant tumor. Science 197: 893–895, 1977

    Article  PubMed  CAS  Google Scholar 

  • Fisher B. Breast cancer: Studies of the National Surgical Adjuvant Primary Breast Cancer Project (NSABP). In Salmon and Jones (Eds) Adjuvant Therapy of Cancer, pp. 215–227, (Elsevier-North Holland Biomedical Press, New York, Amsterdam, 1979

    Google Scholar 

  • Fisher B, Carbone P, Economu S, et al. L-Phenylalanine mustard (L-PAM) in the management of primary breast cancer. New England Journal of Medicine 292: 117–122, 1975

    Article  PubMed  CAS  Google Scholar 

  • Fisher B, Redmond C, Brown A, et al. Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer. Journal of Clinical Oncology 1: 227, 1983

    PubMed  CAS  Google Scholar 

  • Gastrointestinal Tumour Study Group: Adjuvant therapy of colon cancer results of a prospectively randomized trial. New England Journal of Medicine 310: 737–743, 1984

    Article  Google Scholar 

  • Gastrointestinal Tumour Study Group: Prolongation of the disease-free interval in surgically treated rectal carcinoma. New England Journal of Medicine 312: 1465–1472, 1985

    Article  Google Scholar 

  • Glucksburg H, Rivkin SE, Rasmussin S, et al. Combination chemotherapy [CMFVP versus L-phenylalanine mustard (L-PAM)] for operable breast cancer with positive axillary nodes. A Southwest Oncology Group Study. Cancer 50: 423–434, 1982

    Google Scholar 

  • Goldie JH, Coldman AJ. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treatment Reports 63(11–12): 172, 1979

    Google Scholar 

  • Grage TB, Metter GE, Cornell JN, et al. Adjuvant chemotherapy with 5-fluorouracil after surgical resection of colorectal carcinoma (COG Protocol 7041): A preliminary report. American Journal of Surgery 133: 59–66, 1977

    Article  PubMed  CAS  Google Scholar 

  • Greene HSN, Harvey EK. The inhibitory influence of transplanted hamster lymphoma on metastasis. Cancer Research 20: 1094–1100, 1960

    PubMed  CAS  Google Scholar 

  • Grossi CE, Wolff WI, Nealon TF, et al. Intraluminal fluorouracil chemotherapy adjunct to surgical procedures fo resectable carcinoma of the colon and rectum. Surgery, Gynecology and Obstetrics 145: 549–554, 1977

    PubMed  CAS  Google Scholar 

  • Gunduz N, Fisher B, Saffer E. Effect of surgical removal on the growth and kinetics of residual tumor. Cancer Research 39: 3861–3865, 1979

    PubMed  CAS  Google Scholar 

  • Harris J, Hellman S. Local and regional management of carcinoma of the breast. In Carter et al. (Eds) Principles of Cancer Treatment, pp. 296–315 McGraw-Hill, New York, 1982

    Google Scholar 

  • Higgins GA. Chemotherapy, adjuvant to surgery of gastrointestinal cancer. Clinics in Gastroenterology 5: 795–808, 1976

    PubMed  CAS  Google Scholar 

  • Higgins GA, Amadeo JH, McElhinney J, McCaughan JJ, Keehn RJ. Efficacy of prolonged intermittent therapy with combined 5-fluorouracil and methyl-CCNU following resection for carcinoma of the large bowel. Cancer 53: 1–8, 1984

    Article  PubMed  Google Scholar 

  • Higgins GA, Dwight RW, Smith JV. Fluorouracil as an adjuvant to surgery in carcinoma of the colon. Archives of Surgery 102: 339–343, 1971

    Article  PubMed  CAS  Google Scholar 

  • Higgins G, Lee LE, Dwight RW, Keehn RJ. The case for adjuvant 5-fluorouracil in colorectal cancer. Cancer Clinical Trials 1: 35–41, 1978

    Google Scholar 

  • Jaffe N, Frei E, Traggis D, et al. Adjuvant methotrexate and citrovorum factor treatment of osteogenic sarcoma. New England Journal of Medicine 291: 994, 1974

    Article  PubMed  CAS  Google Scholar 

  • Jaffe N, Frei E, Watts H, et al. High-dose methotrexate in osteogenic sarcoma: A 5-year experience. Cancer Treatment Reports 62: 259, 1978

    PubMed  CAS  Google Scholar 

  • Ketcham A, Wexler H, Mantel N. The effect of removal of a ‘primary tumor’ on the development of spontaneous metastases. I. Development of a standardized experimental technique. Cancer Research 19: 940–944, 1959

    CAS  Google Scholar 

  • Lange B, Levine AS. Is it ethical not to conduct a prospectively controlled trial of adjuvant chemotherapy to osteosarcoma. Cancer Treatment Reports 66: 1699–1704, 1982

    PubMed  CAS  Google Scholar 

  • Lawrence WT, Lawrence Jr W. Gastric cancer: The surgeon’s viewpoint. Seminars in Oncology 7: 400–417, 1980

    PubMed  CAS  Google Scholar 

  • Lawrence W, Terz JJ, Horsley JS, Brown PW, Romero C. Chemotherapy as an adjuvant to surgery colorectal cancer. Archives of Surgery 113: 164, 1978

    Article  PubMed  Google Scholar 

  • Link M, Goorin A, Miser A, et al. The role of adjuvant chemotherapy in the treatment of osteosarcoma of the extremity: preliminary results of the Multi-Insitutional Osteosarcoma Study. Proceedings of the ASCO 4: 237, 1985

    Google Scholar 

  • Longmire WP, Kuzma J, Dixon J. The use of triethylene-thiophosphamide as an adjuvant to the surgical treatment of gastric carcinoma. Annals of Surgery 167: 293–312, 1968

    Article  PubMed  Google Scholar 

  • Luria SE, Delbruck M. Mutations of bacteria from virus sensitivity to virus resistance. Genetics 28: 491, 1943

    PubMed  CAS  Google Scholar 

  • Marcove RC. En bloc resection of osteogenic sarcoma. Cancer Treatment Reports 62: 225, 1978

    PubMed  CAS  Google Scholar 

  • Marshall SF. Treatment of cancer of the stomach — end results. Gastroenterology 34: 34–46, 1958

    PubMed  CAS  Google Scholar 

  • Martin DA, Fugman RA. A role for chemotherapy as an adjuvant to surgery. Cancer Research 17: 1098–1101, 1957

    Google Scholar 

  • McNeer G, Lawrence W, Ashley MP. End results in the treatment of gastric cancer. Surgery 43: 879–896, 1958

    PubMed  CAS  Google Scholar 

  • Meakin JW, Allt WEC, Beale FA. Ovarian irradiation and prednisone following surgery for carcinoma of the breast. In Salmon & Jones (Eds) Adjuvant Therapy of Cancer, pp. 95–100 (Elsevier-North Holland Biomedical Press, Amsterdam, 1977

    Google Scholar 

  • Moertel CG, Reitemeier RJ. Advanced gastrointestinal cancer. Clinical chemotherapy of solid tumors. Cancer Chemotherapy Reports 6 (Part 3): 399–419, 1975

    Google Scholar 

  • Nolvadex Adjuvant Trial Organization: Controlled trial of tamoxifen as adjuvant agent in the management of early breast cancer. Lancet 1: 257–261, 19

  • Panettiere FJ, Chen T. Update on the SWOG colorectal adjuvant study of 620 patients. Proceedings of AACR-ASCO 22: 353, 1972

    Google Scholar 

  • Ransom HK. Subtotal gastrectomy for gastric ulcer: A study of end results. Annals of Surgery 126: 633–654, 1947

    Article  Google Scholar 

  • Rockette HE, Redmond CK, Fisher B, et al. Impact of randomized clinical trials on therapy of primary breast cancer. The NSABP overview. Controlled Clinical Trials 3: 209–225, 1982

    Article  CAS  Google Scholar 

  • Rosen G, Nirenberg A. Chemotherapy for osteogenic sarcoma: An investigative method, not a recipe. Cancer Treatment Reports 66: 1687–1697, 1982

    PubMed  CAS  Google Scholar 

  • Rosenberg SA, Chabner B, Young R, et al. The treatment of osteogenic sarcoma. I. Effect of adjuvant high-dose methotrexate following amputation. Cancer Treatment Reports 63: 739, 1979

    Google Scholar 

  • Rosenberg SA, Suit H, Baker LH, Rosen G. Sarcomas of the soft tissue and bone. In DeVita et al. (Eds) Principles and Practice of Oncology, pp. 1036–1093 J.B. Lippincott Co., Philadelphia, 1982

    Google Scholar 

  • Rossi A, Bonadonna G, Valagussa P, et al. CMF adjuvant program for breast cancer. 5-year results. Proceedings of PAACR-ASCO 21: 404, 1980

    Google Scholar 

  • Schatten WE. An experimental study of postoperative tumor metastases. I. Growth of pulmonary metastases following total removal of primary leg tumor. Cancer 2: 455–459, 1958

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Bristol-Myers Company, Pharmaceutical Research and Development Division, Anti-Cancer Research, 345 Park Avenue, New York, NY, 10154, USA

    Stephen K. Carter

Authors
  1. Stephen K. Carter
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Carter, S.K. Adjuvant Chemotherapy of Cancer. Drugs 31, 337–367 (1986). https://doi.org/10.2165/00003495-198631040-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-198631040-00004

Keywords

Search

Navigation